Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.44 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084357 | 0.95 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL14075778 | 0.95 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13046095 | 0.95 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13863569 | 0.95 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL29672354 | 0.87 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL17677178 | 0.87 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL29672348 | 0.87 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13084423 | 0.86 | LMNA (0.52) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13769463 | 0.85 | LMNA (0.59) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL17213531 | 0.84 | LMNA (0.57) | LMNAP2RX3P2RX4P2RX2ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | LMNA 3103/4885P2RX3 20/4885P2RX4 50/4885 |
| US-20080009461-A1 | Therapeutic compounds | ADORA2A, ADORA2B, ADORA1 | LMNA 752/4885P2RX3 6/4885P2RX4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.